Merck to acquire Oncolmmune, accelerating development of COVID-19 treatment candidate

Merck will acquire Oncolmmune for an upfront payment of $425m: pledging to accelerate the development of CD24Fc, a candidate for the treatment of patients with severe and critical COVID-19.